Margherita Nannini

List of Publications by Year
in descending order

115 papers	2,513 citations	186265 28 h-index	243625 44 g-index
116 all docs	116 docs citations	116 times ranked	3263 citing authors

#	Article	IF	Citations
1	Gene expression profiling in colorectal cancer using microarray technologies: Results and perspectives. Cancer Treatment Reviews, 2009, 35, 201-209.	7.7	151
2	Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFRA wild-type GIST. European Journal of Human Genetics, 2014, 22, 32-39.	2.8	90
3	Quadruple wildâ€type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways. Cancer Medicine, 2015, 4, 101-103.	2.8	80
4	An overview on molecular biology of KIT/PDGFRA wild type (WT) gastrointestinal stromal tumours (GIST). Journal of Medical Genetics, 2013, 50, 653-661.	3.2	78
5	Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. World Journal of Gastroenterology, 2016, 22, 519.	3.3	78
6	A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. Laboratory Investigation, 2010, 90, 1285-1294.	3.7	77
7	Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093693.	3.2	71
8	Insulinâ€like growth factor 1 receptor expression in wildâ€type GISTs: A potential novel therapeutic target. International Journal of Cancer, 2009, 125, 2991-2994.	5.1	70
9	Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer, 2014, 14, 685.	2.6	70
10	Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. Pharmacological Research, 2013, 68, 1-6.	7.1	64
11	Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis. Autophagy, 2017, 13, 452-463.	9.1	59
12	Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. Cancer Treatment Reviews, 2008, 34, 103-121.	7.7	54
13	Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. Molecular Cancer Research, 2017, 15, 553-562.	3.4	53
14	Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). Oncology Reports, 2009, 21, 1359-66.	2.6	52
15	Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). BMC Genomics, 2015, 16, 892.	2.8	48
16	Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. British Journal of Cancer, 2008, 99, 1729-1734.	6.4	46
17	Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer, 2012, 12, 231.	2.6	44
18	Genomic Database Analysis of Uterine Leiomyosarcoma Mutational Profile. Cancers, 2020, 12, 2126.	3.7	44

#	Article	IF	Citations
19	The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST). Journal of Translational Medicine, 2017, 15, 113.	4.4	43
20	The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting. Journal of Translational Medicine, 2011, 9, 75.	4.4	41
21	Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. Genetics in Medicine, 2015, 17, 391-395.	2.4	41
22	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. OncoImmunology, 2019, 8, e1617588.	4.6	41
23	A Distinct Pediatric-type Gastrointestinal Stromal Tumor in Adults. American Journal of Surgical Pathology, 2011, 35, 1750-1752.	3.7	40
24	Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer. Annals of Oncology, 2009, 20, 213-226.	1.2	37
25	Current status of the adjuvant therapy in uterine sarcoma: A literature review. World Journal of Clinical Cases, 2019, 7, 1753-1763.	0.8	34
26	Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis. International Journal of Molecular Sciences, 2015, 16, 15592-15608.	4.1	32
27	Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. Journal of Experimental and Clinical Cancer Research, 2010, 29, 173.	8.6	31
28	Expression of IGF-1 receptor in KIT/PDGF receptor-Î± wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction. Future Oncology, 2013, 9, 121-126.	2.4	30
29	Three cases of bone metastases in patients with gastrointestinal stromal tumors. Rare Tumors, 2011, 3, 51-53.	0.6	29
30	Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. International Journal of Molecular Sciences, 2018, 19, 732.	4.1	29
31	11C-Acetate PET for Early Prediction of Sunitinib Response in Metastatic Renal Cell Carcinoma. Tumori, 2009, 95, 382-384.	1.1	28
32	18F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879356.	3.2	28
33	miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers. Epigenomics, 2015, 7, 1033-1049.	2.1	27
34	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591879462.	3.2	27
35	Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis. Cancers, 2020, 12, 1899.	3.7	26
36	Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors. Epigenomics, 2016, 8, 1347-1366.	2.1	23

#	Article	IF	Citations
37	Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours. Histopathology, 2011, 59, 1071-1080.	2.9	22
38	Microscopic Margins of Resection Influence Primary Gastrointestinal Stromal Tumor Survival. Oncology Research and Treatment, 2012, 35, 645-648.	1.2	22
39	SDHC methylation in gastrointestinal stromal tumors (GIST): a case report. BMC Medical Genetics, 2015, 16, 87.	2.1	22
40	Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RASâ€Ƥ WT GIST. Genes Chromosomes and Cancer, 2019, 58, 636-642.	2.8	22
41	The Emerging Role of the FGF/FGFR Pathway in Gastrointestinal Stromal Tumor. International Journal of Molecular Sciences, 2020, 21, 3313.	4.1	22
42	Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. World Journal of Gastroenterology, 2014, 20, 7049.	3.3	22
43	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. Therapeutic Advances in Medical Oncology, 2017, 9, 731-739.	3.2	20
44	An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. Pharmacogenomics Journal, 2019, 19, 390-400.	2.0	20
45	Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFRÎ± genotype evaluated by next generation sequencing (NGS). Oncotarget, 2015, 6, 42243-42257.	1.8	20
46	Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. Tumor Biology, 2016, 37, 13413-13423.	1.8	19
47	Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor. Rare Tumors, 2011, 3, 153-154.	0.6	18
48	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clinical Cancer Research, 2022, 28, 1672-1679.	7.0	18
49	Liquid biopsy in gastrointestinal stromal tumors: a novel approach. Journal of Translational Medicine, 2014, 12, 210.	4.4	17
50	Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. European Journal of Human Genetics, 2015, 23, 817-823.	2.8	17
51	Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. Oncotarget, 2017, 8, 60036-60045.	1.8	17
52	Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Oncotarget, 2016, 7, 69412-69419.	1.8	17
53	Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFRA wild-type metastatic gastrointestinal stromal tumours. Anti-Cancer Drugs, 2012, 23, 567-572.	1.4	16
54	Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST. Frontiers in Oncology, 2020, 10, 504.	2.8	16

#	Article	IF	Citations
55	Targeted therapy in SDH-deficient GIST. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110232.	3.2	16
56	To widen the setting of cancer patients who could benefit from metronomic capecitabine. Cancer Chemotherapy and Pharmacology, 2009, 64, 189-193.	2.3	15
57	Clinical relevance of circulating molecules in cancer: focus on gastrointestinal stromal tumors. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983190.	3.2	15
58	Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma. BMC Research Notes, 2015, 8, 325.	1.4	14
59	Molecular Imaging Suggests Efficacy of Bevacizumab beyond the Second Line in Advanced Colorectal Cancer Patients. Chemotherapy, 2008, 54, 421-424.	1.6	13
60	Genetic aberrations and molecular biology of cardiac sarcoma. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592091849.	3.2	13
61	The Identity of PDGFRA D842V-Mutant Gastrointestinal Stromal Tumors (GIST). Cancers, 2021, 13, 705.	3.7	13
62	The emerging role of insulin-like growth factor 1 receptor (IGF1r) in gastrointestinal stromal tumors (GISTs). Journal of Translational Medicine, 2010, 8, 117.	4.4	11
63	Familial adenomatosis polyposisâ€“related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. ESMO Open, 2020, 5, e000604.	4.5	11
64	Treatments for gastrointestinal stromal tumors that are resistant to standard therapies. Future Oncology, 2014, 10, 2045-2059.	2.4	10
65	An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. Angiogenesis, 2017, 20, 139-148.	7.2	10
66	The rs17084733 variant in the KIT 3â€™ UTR disrupts a miR-221/222 binding site in gastrointestinal stromal tumour: a sponge-like mechanism conferring disease susceptibility. Epigenetics, 2019, 14, 545-557.	2.7	10
67	Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation. Frontiers in Immunology, 2020, 11, 851.	4.8	10
68	Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study. ESMO Open, 2021, 6, 100222.	4.5	10
69	Clinical, radiological and biological features of lung metastases in gastrointestinal stromal tumors (case reports). Oncology Reports, 2011, 25, 113-20.	2.6	10
70	Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors. Clinical Sarcoma Research, 2014, 4, 9.	2.3	9
71	Gene Expression Landscape of SDH-Deficient Gastrointestinal Stromal Tumors. Journal of Clinical Medicine, 2021, 10, 1057.	2.4	9
72	Molecular Imaging of EGFR: It's Time to Go Beyond Receptor Expression. Journal of Nuclear Medicine, 2009, 50, 1195-1196.	5.0	7

#	Article	IF	Citations
73	Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib. Case Reports in Oncology, 2012, 5, 651-656.	0.7	7
74	Late recurrences of gastrointestinal stromal tumours (GISTs) after 5Âyears of follow-up. Medical Oncology, 2012, 29, 144-150.	2.5	7
75	Characterization of malignant gastrointestinal stromal tumorsâ€"a single center experience. Journal of Gastrointestinal Oncology, 2017, 8, 1037-1045.	1.4	7
76	Successful multidisciplinary clinical approach and molecular characterization by whole transcriptome sequencing of a cardiac myxofibrosarcoma: A case report. World Journal of Clinical Cases, 2019, 7, 3018-3026.	0.8	7
77	Uterine Preservation Treatments in Sarcomas: Oncological Problems and Reproductive Results: A Systematic Review. Cancers, 2021, 13, 5808.	3.7	7
78	Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy. Cancer Treatment Reviews, 2010, 36, 63-68.	7.7	6
79	Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report. International Journal of Surgery Case Reports, 2013, 4, 7-10.	0.6	6
80	Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours. Oncology Letters, 2014, 8, 1793-1799.	1.8	6
81	Unusual bilateral ovarian metastases from ileal gastrointestinal stromal tumor (GIST): a case report. BMC Cancer, 2018, 18, 301.	2.6	6
82	What oncologists need and require from nuclear medicine. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 1761-1765.	6.4	5
83	Unusual Finding of Benign Abrikossoff Tumor by F-18 FDG-PET Mimicking Melanoma Recurrence. Clinical Nuclear Medicine, 2009, 34, 696-697.	1.3	5
84	Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice. Targeted Oncology, 2012, 7, 243-246.	3.6	5
85	Duration of adjuvant treatment following radical resection of metastases from gastrointestinal stromal tumours. Oncology Letters, 2012, 3, 677-681.	1.8	5
86	Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. Anti-Cancer Drugs, 2016, 27, 353-363.	1.4	5
87	Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRÎ± mutation in a metastatic GIST patient responding to imatinib. Scientific Reports, 2019, 9, 2172.	3.3	5
88	What is changing in the surgical treatment of gastrointestinal stromal tumors after multidisciplinary approach? A comprehensive literature's review. Minerva Surgery, 2017, 72, 219-236.	0.6	5
89	Whole Exome Sequencing Uncovers Germline Variants of Cancer-Related Genes in Sporadic Pheochromocytoma. International Journal of Genomics, 2018, 2018, 1-9.	1.6	4
90	A Single-Centre Experience on the Management of Adenosarcoma: A Successful Report of an Integrated Medical and Surgical Approach. Clinical Medicine Insights: Oncology, 2018, 12, 117955491878247.	1.3	4

#	Article	IF	Citations
91	Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma. International Journal of Molecular Sciences, 2018, 19, 1855.	4.1	4
92	Granular cell tumor of the trachea as a rare cause of dyspnea in a young woman. Respiratory Medicine Case Reports, 2019, 28, 100961.	0.4	4
93	Complete radiological response to first-line regorafenib in a patient with abdominal relapse of BRAF V600E mutated GIST. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482092730.	3.2	4
94	SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor. Frontiers in Oncology, 2021, 11, 778461.	2.8	4
95	Analysis of microbiome in gastrointestinal stromal tumors: Looking for different players in tumorigenesis and novel therapeutic options. Cancer Science, 2022, 113, 2590-2599.	3.9	4
96	Molecular detection of epidermal growth factor receptor in colorectal cancer: does it still make sense?. Colorectal Disease, 2011, 13, 542-548.	1.4	3
97	Skull Metastasis From Uterine Leiomyosarcoma, a Rare Presentation for a Rare Tumor: A Case Report and Review of the Literature. Frontiers in Oncology, 2020, 10, 869.	2.8	3
98	Primary malignant pericardial tumour in Lynch syndrome. BMC Cancer, 2020, 20, 191.	2.6	3
99	The Response Evaluation Criteria in Solid Tumors: until when?. Nuclear Medicine Communications, 2009, 30, 185-187.	1.1	2
100	Role of molecular analysis in the adjuvant treatment of gastrointestinal stromal tumours: It is time to define it. World Journal of Gastroenterology, 2013, 19, 2583.	3.3	2
101	New molecular targets beyond KIT and PDGFRA in gastrointestinal stromal tumors: present and future. Expert Opinion on Therapeutic Targets, 2011, 15, 803-815.	3.4	1
102	An immunohistochemical study of potential diagnostic and therapeutic biomarkers of wildâ€type gastrointestinal stromal tumours. Histopathology, 2015, 67, 746-747.	2.9	1
103	Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experience.. Journal of Clinical Oncology, 2014, 32, 10515-10515.	1.6	1
104	Molecular imaging and targeted therapies in oncology: New concepts in treatment response assessment. A collection of cases. International Journal of Oncology, 1992, , .	3.3	1
105	Insulin-like Growth Factor (IGF) system and gastrointestinal stromal tumours (GIST): present and future. Histology and Histopathology, 2014, 29, 167-75.	0.7	1
106	Management of Patients with Gastrointestinal Stromal Tumor in Clinical Practice in Italy: A Critical â€œEvent Tree Modelâ€•Analysis of Decision-Making Processes and Outcomes. Tumori, 2010, 96, 219-228.	1.1	0
107	The Follow-up After Radical Surgery of Colorectal Cancer: Is it Time for a â€œTailoredâ€•Strategy?. Clinical Colorectal Cancer, 2011, 10, 81-84.	2.3	0
108	Novel Clinically Relevant Genes in GISTâ€”Letter. Clinical Cancer Research, 2014, 20, 2014-2014.	7.0	0

#	Article	IF	Citations
109	Long-term outcome of molecular subgroups of gastrointestinal stromal tumour patients treated with standard-dose imatinib in the BFR14 trial: The wild-typeÂgastrointestinal stromal tumours are not a single group yet. European Journal of Cancer, 2016, 58, 38-40.	2.8	0
110	Personalized Medicine in Gastrointestinal Stromal Tumors. , 2019, , 329-337.		0
111	Living Donor Liver Transplantation for Imatinibâ€Resistant Gastrointestinal Stromal Tumor Liver Metastases: A New Therapeutic Option in Transplant Oncology. Liver Transplantation, 2020, 26, 1373-1374.	2.4	0
112	Letter to the editor concerning â€œLiver transplantation for metastatic wildâ€type gastrointestinal stromal tumor in the era of molecular targeted therapies: Report of a first case". American Journal of Transplantation, 2020, 20, 3701-3702.	4.7	0
113	Integrate whole genomic study of KIT/PDGFRA wild-type (WT) GIST.. Journal of Clinical Oncology, 2014, 32, 10513-10513.	1.6	0
114	Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).. Journal of Clinical Oncology, 2019, 37, 11032-11032.	1.6	0
115	Update of NGS analysis of Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor).. Journal of Clinical Oncology, 2020, 38, e23518-e23518.	1.6	0